Return to the Faculty List

Nuri B. Farber, MD

Current Position
Professor of Psychiatry

University Roles
Director, Psychiatry Residency Training Program
Co-Director, Animal Neuropathology Core Facility

Education and Training
B.A.: Washington University, St. Louis, Missouri, 1985
Medical Degree: Washington University, St. Louis, Missouri, 1989
Residency: Washington University, St. Louis, Missouri, St. Louis, Missouri, 1993

Major Awards
Excellence in Teaching Award, 1993
The Sandoz Award, In recognition of superior academic achievement and contribution, 1989

Areas of Clinical Interest
psychosis, ECT, Alzheimer's disease, mental retardation, schizophrenia, major depression, psychopharmacology

Areas of Research Interests
My research focuses are both clinical and basic science. Clinically I am currently studying the use of ketamine for treatment resistant depression. Our current goal is to evaluate the utility of a 96-hour subchronic dosing approach. In basic science I focus on the ability of neuroactive chemicals/compounds, prescribed drugs, and abused drugs to injure/kill neurons and glia in the CNS. Most of these agents appear to produce injury by inhibiting neuronal activity (e.g. NMDA antagonists, GABA mimetics, anticonvulsants). Other agents (e.g. solvents) have a less clear mechanism. Techniques used in the lab are pharmacological, histochemical (light and EM), neuroanatomical and cognitive/behavioral in nature. Results could be important for understanding childhood developmental disorders like mental retardation, autism, ADHD, Fetal Alcohol Syndrome as well as adult disorders such as schizophrenia, bipolar disorder and Alzheimer's disease.

More articles and abstracts at the National Library of Medicine

Key Publications
Lenze EJ, Farber NB, Kharasch E, Schweiger J, Yingling M, Olney J, Newcomer JW (2016 Apr). Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial. World J Biol Psychiatry. (3):230-8  Full Article ->

Farber NB, (2018 Nov). NMDA Antagonists for Treatment-Resistant Depression. Handb Exp Pharmacol.   Full Article ->

Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW (1999 Feb). Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 20(2): 106-18.  Full Article ->

Farber NB (2003 Nov). The NMDA receptor hypofunction model of psychosis. Ann N Y Acad Sci. 1003119-30.  Full Article ->

Noguchi KK, Cabrera OH, Swiney BS, Salinas-Contreras P, Smith JK, Farber NB (2015 Nov). Hedgehog regulates cerebellar progenitor cell and medulloblastoma apoptosis. Neurobiol Dis. 83:35-43.  Full Article ->

Farber NB, Creeley CE, Olney JW (2010 Oct). Alcohol-induced neuroapoptosis in the fetal macaque brain. Neurobiol Dis. 40(1): 200-6.  Full Article ->

Funded Research Projects
James S. McDonnell Foundation(Significant Contributor):Reconstructing Consciousness and Cognition, Phase 2
NICHD(Significant Contributor):Washington University Intellectual and Developmental Disabilities Research Center
Missouri SCIDRP(Significant Contributor):Anesthesia Induced Apoptosis in the Developing Spinal Cord
NIDDK(Significant Contributor):Targeting Endoplasmic Reticulum for the Treatment of Wolfram Syndrome
ICTS(PI):Maintaining Response to Ketamine in Patients with Major Depression
NCATS(Significant Contributor):An Endoplasmic Reticulum Calcium Stabilizer for the Treatment of Wolfram Syndrome
NICHD(Significant Contributor):Anesthesia Toxicity in Neonatal Primate Brain
NIMH(Significant Contributor):Washington University Psychiatry Residency Research Education Program
NIMH(Significant Contributor):Brain and Cognitive Dynamics Following Electroconvulsive Therapy and Concurrent Anesthetic